Iwabuchi Minami, Narita Miwako, Uchiyama Takayoshi, Iwaya Shunpei, Oiwa Eri, Nishizawa Yoshinori, Hashimoto Shigeo, Bonehill Aude, Kasahara Noriyuki, Takizawa Jun, Takahashi Masuhiro
Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Nagaoka, Niigata 951‑8518, Japan.
Division of Hematology, Nagaoka Red Cross Hospital, Nagaoka, Niigata 951‑8518, Japan.
Mol Med Rep. 2015 Aug;12(2):2443-50. doi: 10.3892/mmr.2015.3685. Epub 2015 Apr 24.
The aim of the present study was to enhance the efficiency of leukemia immunotherapy by increasing the antigen-specific cytotoxic T lymphocyte-inducing ability of leukemia cells. The leukemic plasmacytoid dendritic cell line PMDC05 containing the HLA-A02/24 antigen, which was previously established in our laboratory (Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata, Japan), was used in the present study. It exhibited higher expression levels of CD80 following transduction with lentiviruses encoding the CD80 gene. This CD80-expressing PMDC05 was named PMDC11. In order to establish a more potent antigen-presenting cell for cellular immunotherapy of tumors or severe infections, PMDC11 cells were transduced with a constitutively active (ca) toll-like receptor 4 (TLR4) gene using the Tet-On system (caTLR4-PMDC11). CD8(+) T cells from healthy donors with HLA-A02 were co-cultured with mutant WT1 peptide-pulsed PMDC11, lipopolysaccharide (LPS)-stimulated PMDC11 or caTLR4-PMDC11 cells. Interleukin (IL)-2 (50 IU/ml) and IL-7 (10 ng/ml) were added on day three of culture. Priming with mutant WT1 peptide-pulsed PMDC11, LPS-stimulated PMDC11 or caTLR4-PMDC11 cells was conducted once per week and two thirds of the IL-2/IL-7 containing medium was replenished every 3-4 days. Immediately prior to the priming with these various PMDC11 cells, the cultured cells were analyzed for the secretion of interferon (IFN)-γ in addition to the percentage and number of CD8(+)/WT1 tetramer(+) T cells using flow cytometry. caTLR4-PMDC11 cells were observed to possess greater antigen-presenting abilities compared with those of PMDC11 or LPS-stimulated PMDC11 cells in a mixed leukocyte culture. CD8 T cells positive for the WT1 tetramer were generated following 3-4 weeks of culture and CD8(+)/WT1 tetramer+ T cells were markedly increased in caTLR4-PMDC11-primed CD8(+) T cell culture compared with PMDC11 or LPS-stimulated PMDC11-primed CD8(+) T cell culture. These CD8(+) T cells co-cultured with caTLR4-PMDC11 cells were demonstrated to secrete IFN-γ and to be cytotoxic to WT1-expressing target cells. These data suggested that the antigen-specific cytotoxic T lymphocyte (CTL)-inducing ability of PMDC11 was potentiated via transduction of the caTLR4 gene. The present study also suggested that caTLR4-PMDC11 cells may be applied as potent antigen-presenting cells for generating antigen-specific CTLs in adoptive cellular immunotherapy against tumors and severe viral infections.
本研究的目的是通过提高白血病细胞诱导抗原特异性细胞毒性T淋巴细胞的能力,来增强白血病免疫治疗的效率。本研究使用了白血病浆细胞样树突状细胞系PMDC05,其含有HLA - A02/24抗原,该细胞系先前由我们实验室(日本新潟大学健康科学研究生院血液学与肿瘤学实验室)建立。在用编码CD80基因的慢病毒转导后,它表现出更高水平的CD80表达。这种表达CD80的PMDC05被命名为PMDC11。为了建立一种更有效的用于肿瘤或严重感染细胞免疫治疗的抗原呈递细胞,使用Tet - On系统用组成型活性(ca)Toll样受体4(TLR4)基因转导PMDC11细胞(caTLR4 - PMDC11)。将来自具有HLA - A02的健康供体的CD8(+) T细胞与经突变WT1肽脉冲处理的PMDC11、脂多糖(LPS)刺激的PMDC11或caTLR4 - PMDC11细胞共培养。在培养的第三天加入白细胞介素(IL)-2(50 IU/ml)和IL -7(10 ng/ml)。每周用经突变WT1肽脉冲处理的PMDC11、LPS刺激的PMDC11或caTLR4 - PMDC11细胞进行一次致敏,并每3 - 4天补充三分之二含IL -2/IL -7的培养基。就在用这些不同的PMDC11细胞进行致敏之前,除了使用流式细胞术分析CD8(+)/WT1四聚体(+) T细胞的百分比和数量外,还分析培养细胞中干扰素(IFN)-γ的分泌情况。在混合白细胞培养中,观察到caTLR4 - PMDC11细胞比PMDC11或LPS刺激的PMDC11细胞具有更强的抗原呈递能力。培养3 - 4周后产生了WT1四聚体阳性CD8 T细胞,与PMDC11或LPS刺激的PMDC11致敏的CD8(+) T细胞培养相比,在caTLR4 - PMDC11致敏的CD8(+) T细胞培养中CD8(+)/WT1四聚体+ T细胞明显增加。与caTLR4 - PMDC11细胞共培养的这些CD8(+) T细胞被证明可分泌IFN -γ并对表达WT1的靶细胞具有细胞毒性。这些数据表明,通过转导caTLR4基因可增强PMDC11诱导抗原特异性细胞毒性T淋巴细胞(CTL)的能力。本研究还表明,caTLR4 - PMDC11细胞可作为有效的抗原呈递细胞,用于在针对肿瘤和严重病毒感染的过继性细胞免疫治疗中产生抗原特异性CTL。